Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 19.0

Eligibility Criteria:
Inclusion Criteria for Parts A \& B:~* Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception.~* Willing to provide written informed consent and comply with study requirements~Additional Inclusion Criteria for Part B:~* Diagnosis of chronic HBV infection~* Hepatitis B surface antigen (HbsAg) at screening \> or = 50 IU/mL~* Liver Elastography score \< or = 10.5~Exclusion Criteria:~* Clinically significant health concerns (with the exception of HBV for Patients in Part B)~* Abnormal for any clinical safety laboratory result considered clinically significant~* Regular use of alcohol within 1 month prior to screening~* Recent use of illicit drugs~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study~NOTE: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ARO-HBV 35 mg (Type: EXPERIMENTAL): Single dose of ARO-HBV 35 mg subcutaneous (sc) injection in normal healthy volunteers
- ARO-HBV 100 mg (Type: EXPERIMENTAL): Single dose of ARO-HBV 100 mg sc injection in normal healthy volunteers
- ARO-HBV 200 mg (Type: EXPERIMENTAL): Single dose of ARO-HBV 200 mg sc injection in normal healthy volunteers
- ARO-HBV 300 mg (Type: EXPERIMENTAL): Single dose of ARO-HBV 300 mg sc injection in normal healthy volunteers
- ARO-HBV 400 mg (Type: EXPERIMENTAL): Single dose of ARO-HBV 400 mg sc injection in normal healthy volunteers
- Placebo (Type: PLACEBO_COMPARATOR): Sterile normal saline (0.9% NaCl) sc injection in normal healthy volunteers
- ARO-HBV 25 mg, Q28D (Type: EXPERIMENTAL): ARO-HBV 25 mg sc injection every 28 days (Q28D) in participants with chronic hepatitis B
- ARO-HBV 50 mg Q28D (Type: EXPERIMENTAL): ARO-HBV 50 mg sc injection Q28D in participants with chronic hepatitis B
- ARO-HBV 100 mg Q28D (Type: EXPERIMENTAL): ARO-HBV 100 mg sc injection Q28D in participants with chronic hepatitis B
- ARO-HBV 200 mg Q28D (Type: EXPERIMENTAL): ARO-HBV 200 mg sc injection Q28D in participants with chronic hepatitis B
- ARO-HBV 300 mg Q28D (Type: EXPERIMENTAL): ARO-HBV 300 mg sc injection Q28D in participants with chronic hepatitis B
- ARO-HBV 400 mg Q28D (Type: EXPERIMENTAL): ARO-HBV 400 mg sc injection Q28D in participants with chronic hepatitis B
- ARO-HBV 100 mg Q14D (Type: EXPERIMENTAL): ARO-HBV 100 mg sc injection every 14 days (Q14D) in participants with chronic hepatitis B
- ARO-HBV 100 mg Q7D (Type: EXPERIMENTAL): ARO-HBV 100 mg sc injection every 7 days (Q7D) in participants with chronic hepatitis B
- ARO-HBV 300 mg, Q28D, HBeAg+/ Trt Naïve (Type: EXPERIMENTAL): ARO-HBV 300 mg sc injection Q28D in hepatitis B e antigen positive/treatment naïve (HBeAg+/Trt Naïve) participants with chronic hepatitis B
- ARO-HBV 300 mg, Q28D, HBeAg+/ NUC (Type: EXPERIMENTAL): ARO-HBV 300 mg sc injection Q28D in HBeAg+/nucleotide or nucleoside analog treated (HBeAg+/NUC) participants with chronic hepatitis B
- ARO-HBV 200 mg, Q7D (Type: EXPERIMENTAL): ARO-HBV 200 mg sc injection Q7D in participants with chronic hepatitis B
- ARO-HBV 300 mg, Q7D (Type: EXPERIMENTAL): ARO-HBV 300 mg sc injection Q7D in participants with chronic hepatitis B
- ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg (Type: EXPERIMENTAL): ARO-HBV 200 mg sc injection Q28D plus JNJ-56136379 250 mg in participants with chronic hepatitis B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete